Tuberculosis and HIV: latest news

Tuberculosis and HIV resources

  • Tuberculosis

    Tuberculosis (TB) is an infection that usually affects the lungs.It can be very serious, particularly for people living with HIV who have a low CD4 count.TB can...

    From: Factsheets

    Information level Level 2
  • TB and HIV

    If HIV has weakened your immune system, you are more vulnerable to tuberculosis (TB). TB is an infection caused by bacteria. It is a serious...

    From: The basics

    Information level Level 1
  • How TB is passed on

    The bacteria that cause tuberculosis (TB) can sometimes pass from one person to another through the air. TB bacteria can sometimes be spread through the...

    From: The basics

    Information level Level 1
  • Treatment for TB and HIV

    If tuberculosis (TB) is making you ill and you also have HIV, then you usually need to take treatment for both TB and HIV.You can...

    From: The basics

    Information level Level 1
  • Diagnosed with HIV at a low CD4 count

    NAM's factsheet on being diagnosed with HIV when already at a low CD4 cell count...

    From: Factsheets

    Information level Level 2

Tuberculosis and HIV features

Tuberculosis and HIV in your own words

Tuberculosis and HIV news from aidsmap

More news

Tuberculosis and HIV news selected from other sources

  • High rates of HIV and diabetes raise the risk of TB for South Africans

    The Yale-led research team analyzed health data on more than 7,000 patients screened for both chronic and infectious diseases. After adjusting for demographic and socioeconomic factors, the researchers found that people with either HIV or diabetes were more likely to also have TB. They also discovered that having both diseases further compounded the risk for developing TB symptoms. This is one of the first studies to demonstrate the possible synergism between HIV and diabetes to increase risk of TB, the researchers said.

    20 June 2018 | Yale News
  • All-access for blockbuster TB drug in South Africa

    The country made history on Monday when the health department announced that all drug-resistant tuberculosis (DR-TB) patients will be eligible to receive the new medicine, bedaquiline. “The Department of Health’s [DoH] commitment on bedaquiline is momentous globally and marks a new era of DR-TB management where we are really prioritising the patient,” Doctors Without Borders’ Dr Anja Reuters told Health-e News.

    19 June 2018 | Health-e
  • Scientists join forces to fight TB and HIV in EUR 12.9 million TREATS trial

    The EUR 12.9 million project, featuring a number of international institutions including Imperial College London, will measure the impact of combined tuberculosis (TB) and HIV interventions on over one million people in communities across Zambia and South Africa.

    01 May 2018 | Imperial College London
  • Study finds more than 80 percent of patients needing WHO recommended last resort treatment for drug-resistant TB not getting it

    Roughly four years after the World Health Organization recommended that the newest drugs against tuberculosis be made available to patients for whom they represented a last resort, fewer than a fifth of patients needing them have received them, according to a report in the International Journal of Tuberculosis and Lung Disease.

    06 April 2018 | Science Speaks
  • UNAIDS calls for bold action to end TB and AIDS

    Ahead of World TB Day 2018, UNAIDS is calling on all partners to take unprecedented and bold action to advance efforts to end tuberculosis (TB) and AIDS by 2030.

    23 March 2018 | UNAIDS
  • WHO issues recommendations on management of isoniazid-resistant tuberculosis

    Within the context of an ongoing extensive review of evidence on treatment of drug-resistant (TB) taking place in 2018, the World Health Organization (WHO) has issued a Supplement to its current drug-resistant TB treatment guidelines, providing recommendations for the management of isoniazid-resistant TB. These will be incorporated into the Consolidated Guidelines for Treatment and Care of Drug-resistant TB envisaged by WHO later in 2018.

    22 March 2018 | World Health Organization
  • Higher rifampin doses safe for patients with pulmonary TB

    Results of a phase 2 randomized clinical trial show that up to twice the standard daily dose of rifampin was safe in patients with pulmonary tuberculosis. The findings suggest that TB therapy can be shortened using higher doses, which could potentially improve outcomes without increasing toxicity.

    07 March 2018 | Healio
  • Dolutegravir and Rifapentine study stopped due to serious toxicities

    A study examining pharmacokinetic interactions between the first-line HIV drug dolutegravir and a once-weekly tuberculosis regimen was terminated early after NIH researchers found that the combined use of the treatments led to “unexpected and serious toxicities” in healthy participants.

    01 March 2018 | Medical Brief
  • TB treatment outcomes good for multidrug-resistant TB/HIV co-infected patients who start ART

    Treatment of multidrug-resistant tuberculosis (TB) has comparable efficacy and survival rates in patients infected with HIV and not uninfected with HIV when patients with HIV are given antiretroviral therapy.

    01 February 2018 | Medical Brief
  • An Inside Look At Ukraine's Terrifying TB Outbreak

    Strains of drug-resistant tuberculosis are spreading across Ukraine, where armed conflict and market misgivings are making a bad situation even worse.

    07 January 2018 | Worldcrunch / Suddeutsche Zeitung
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.